Plus Therapeutics Provides A Business Update For Its Wholly-owned Subsidiary, CNSide Diagnostics, The CNSide Cerebrospinal Fluid Assay Platform Is Designed And Intended For Patients Suspected Of Having Central Nervous System Cancer Metastases
Benzinga · 7h ago
Share
Listen to the news
- U.S. commercial rollout of novel diagnostic platform to begin second half 2025
- Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved